Target intelligence / Profile preview

1,3-beta-glucan synthase (Fks1) (Fks1)

Target
Fks1
Molecular classification
Enzyme, Membrane protein, Glycosyltransferase (GT-C superfamily)
01

Overview

1,3-beta-glucan synthase (Fks1) is a large, integral membrane glycosyltransferase enzyme found in fungi and some bacteria, responsible for synthesizing β-1,3-glucan—a primary structural component of the fungal cell wall[2][3][4][6][7]. The enzyme complex consists of the catalytic Fks1 subunit and regulators (e.g., Rho1 GTPase), and resides in the plasma membrane[3]. It catalyzes the polymerization of glucose from UDP-glucose into β-1,3-glucan. Fks1 is essential for fungal cell wall integrity, growth, and viability, and is the molecular target of echinocandin class antifungal drugs and the triterpenoid ibrexafungerp[2][6]. These drugs inhibit Fks1, causing cell wall disruption and cell death. Resistance to these drugs is mainly due to amino acid substitutions in Fks1[7]. Fks1 is classified as a GT-C family member based on its membrane integration and catalytic domain structure[4]. There is no direct therapeutic target known as \"microbial membrane phospholipids\"—phospholipids are broad membrane constituents, not specific drug targets in the same sense as glucan synthase enzymes.

Other names
β-1,3-glucan synthaseβ-glucan synthaseGS complexFks1p
02

Mechanism of action

Inhibition of β-1,3-glucan synthase blocks the synthesis of β-1,3-glucan, leading to fungal cell wall weakening and cell death

03

Biological functions

Cell wall biosynthesisFormation of β-1,3-glucan polysaccharidesStructural support for fungal/microbial cells
04

Disease associations

Infection (antifungal drug target)Other (critical for fungal virulence and cell viability)
05

Safety considerations

Resistance due to mutations in FKS genes (notably FKS1)Mammalian toxicity is minimized as the target is not found in humans, but hypersensitivity and hepatic side effects have been reported with drugs
06

Interacting drugs

Echinocandins (e.g., caspofungin, micafungin, anidulafungin)

1 more in the full profile.

Beyond the preview

Go deeper on 1,3-beta-glucan synthase (Fks1) (Fks1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1,3-beta-glucan synthase (Fks1) (Fks1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call